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E T H I C S I N CA N C E R
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Stacy M Carter
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Abstract
Screening for cancer or cancer risk is well-established in high-income countries. This article considers ethical
aspects of cancer screening. Ethical evaluation of screening depends on a contested evidence base, interacts
with people’s fear of cancer, and their enthusiasm for technology in general and screening in particular. Cancer
screening is both a clinical and a public health activity, and so the often-conflicting frameworks from both clinical
ethics and public health ethics are relevant to its evaluation. Cancer screening is an intrusion by health services into
the lives of well individuals and so requires strong justification. Cancer screening can and should prevent harms
to physical health, but its ability to do so is contingent on many factors and finely balanced; screening can also
affect psychological wellbeing. When communicating about screening programs, care must be taken to support
rather than undermine the autonomy of people considering participation. The benefit offered by cancer screening
programs should be large enough to justify the opportunity costs of screening and the consequent cascade
of intervention. Treatment should be offered in a way that avoids creating financial strain for individuals. Other
relevant ethical issues include equity of opportunity and outcome in screening and accountability to communities.
It is not clear how population-level and individual-level outcomes and interests in cancer screening should be
balanced; future work should focus on resolving these difficult issues.
Screening for cancer or cancer risk is well-established in
high-income countries. In Australia this includes organised
population-based screening programs for breast cancer,
cervical cancer risk and colorectal cancer risk. In addition,
prostate specific antigen (PSA) testing to detect prostate
cancer risk in asymptomatic men is done so frequently
that it has become a de-facto screening program. This
article considers ethical aspects of cancer screening.
Screening is the application of a test (which for practical
reasons must generally be affordable and easy to use) to
large, normal-risk populations of asymptomatic people –
people who appear to be well. This testing is generally
initiated by health authorities rather than individuals.
Screening aims to separate people at higher risk from
those at low risk. Higher risk people then receive diagnostic
testing, and treatment if disease is present.1,2
Ethics addresses the question of what, in any given
situation, is the right or good thing to do, and why those
actions are more justifiable than alternatives. An ethical
evaluation of cancer screening is an analysis of whether
screening for a particular cancer in a certain way is the
right thing to do, and if so, why.

Ethically-relevant contextual issues
An analysis of the ethics of cancer screening occurs in a
context: it depends both on the evidence about screening
and on the culture in which screening occurs.
Screening is usually not initiated by the person
being screened
In ordinary clinical medicine, a patient approaches a health
professional seeking resolution of a symptom or problem.

In contrast, in screening, health authorities encourage
apparently well people to be tested, an act that may turn
them into a sick patient.2 This intrusiveness suggests the
need for a strong justification for screening programs perhaps stronger than for treatments for symptomatic
disease.
Ethics depends
is contested

on

evidence,

but

evidence

Ethical evaluation depends on good evidence, in this
case, epidemiological evidence about the benefits and
harms that screening offers. Unfortunately, the evidencebase for even for the best-established programs is
contested.3-5 It has developed in disparate contexts, and
its coherence and generalisability is often unclear. Experts
disagree on the quality of studies and potential screening
harms are often not studied. These uncertainties hamper
ethical evaluation of screening programs.4
Public perceptions and cultural meanings interact
with moral judgements
Perceptions about cancer can affect people’s moral
judgements about screening. Cancer is an especiallyfeared disease, strongly associated with death.6,7
Screening offers a solution to the problem of cancer
led by technological development, which may increase
its appeal.8,9 There is general enthusiasm for cancer
screening. A US study found that 87% of respondents
believed screening was almost always a good idea
and 32-41% believed that an 80 year-old who did not
participate in screening was irresponsible.10 (Note that an
80 year-old would not ordinarily be screened for cancer:
the investigators asked this question to test how strong
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respondents’ commitment to screening was, even in the
absence of the possibility of benefit.) In an Australian
study, 80% of participants believed early detection saved
lives most or all or the time, and 70% wanted to be tested
even for a cancer that could not be effectively treated.11
This combination (frightening cancer, high-tech solution,
enthusiasm for screening) may make people generally
vulnerable to misperceiving cancer risk, or to taking
up offers of unproven screening tests, and suggests a
heightened responsibility for those who offer screening to
healthy populations.3

Ethical issues in screening activities
Both clinical ethics and public health ethics are
relevant to screening
Cancer screening is both a public health and a clinical
activity.2 It is ‘public’ in that it is used as a tool to improve
the health of the general population, supported by public
funds, organised into national programs that include
public communication campaigns, and is standardised
(e.g. the target group, the test used, the quality of
pathology or radiology services). Although organisation
varies enormously between jurisdictions,12 the resulting
standardisation and improvements in service quality
are important potential shared benefits of organising
screening. This ‘public’ character of screening programs
suggests that frameworks for public health ethics are
likely to be relevant.13 Public health ethics frameworks
emphasise values and principles such as: reasoning
at the level of the population, working for common
good, maximising utility through effective interventions,
distributing opportunities or outcomes fairly, acting in
ways that promote trust in the health system (e.g.
communicating honestly, facilitating public participation),
ensuring that interventions are necessary and proportional
to the problem, and avoiding coercion or restrictions on
important liberties.14-18
Conversely, screening is frequently implemented in cliniclike situations, either by a person’s usual primary care
physician as exemplified by PSA testing and cervical
screening, or by a specialist technician in the case of
mammography. The choice to participate in or refuse
cancer screening is largely a matter for individuals. Unlike
vaccination, where high participation is needed to sustain
herd immunity, there is little common good arising from
an individual’s participation in cancer screening. Thus
the concerns of clinical ethics, such as avoiding harm
to individuals and respecting the decision of individuals
about whether screening is in their best interests for
example, are also relevant.19-21
This ethical tension is not yet resolved. It seems likely
that the public aspects of screening programs should be
assessed according to public health ethics criteria and
the clinical aspects according to clinical ethics criteria.
How we should adjudicate if these come into conflict for example, if seeking informed consent to participate
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decreases population-level mortality benefit or program
cost effectiveness - is not clear.
Cancer screening should protect physical health
and avoid physical harm
Preventing harms to physical health is the stated goal
of most screening programs. Each Australian cancer
screening program, for example, takes as its aim: “to
reduce illness and death from [the relevant] cancer.”22
However, screening alone cannot prevent harms to
physical health (that is, prevent morbidity and mortality
from cancer). This relies on the cascade of diagnostic
testing and treatment that follows screening. 23,24 This
cascade can prevent harms that would have been caused
by cancer. But it can also cause physical harm, such as
pain, disfigurement or functional deficits (for example,
impotence and/or incontinence after prostate biopsy and
treatment). If cancer could be reliably detected, and if all
cancers inevitably and linearly progressed to death, and
if early treatment was always more effective than later
treatment, the harms of the screening cascade would
readily outweigh the harms of cancer. 25 Unfortunately,
benefits and harms in the cascade are often delicately
balanced.
Screening and the resulting cascade will be more likely to
do net harm under the following conditions:
1. When test characteristics are poor, so that large
numbers of low risk people are directed to diagnostic
testing and/or treatment.4,26
2. When treatment for later, symptomatic disease is very
effective, so screening is less necessary.
3. When the disease diagnosed is not destined to
cause harm i.e. when a disease is present, but not
destined to cause symptoms, such that diagnosing
and treating it will cause net harm (the problem known
as overdiagnosis).27-29
4. When the population-level risk of the disease is low,
such that more people will need to be screened to
save one life and more net harm is likely.4,25
What should count as a benefit or a harm of screening is
also not clear. Policymakers, clinicians and citizens have
different views on what is important.30,25,31 For example,
some may wish to avoid every cancer death at any
cost, while others may prioritise avoiding unnecessary
treatment. Determining whether screening prevents harm
requires deciding which harms matter, finding data about
them, and deciding how they should be weighted in
analysis.
Cancer screening and psychological wellbeing
Social marketing about screening commonly suggests
that screening can provide reassurance that disease is
absent.32,33 If this correct, a negative screening result may
CancerForum
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serve the goal of improving psychological wellbeing. 2
However, in population screening, how or when such
reassurance should count as a benefit is not clear.
As noted, fear of cancer is common in populations.
Cancer was historically difficult to treat, and so was
associated with suffering and death. Even after significant
improvements in treatment, cancers are leading causes of
death in middle age in Australia and directly experienced
by many, so some fear of cancer is not unreasonable.34,35
However, fear or anxiety may also arise from public health
communication campaigns designed to encourage people
toward screening or other health behaviour change.36,37
That is, at least some anxiety about cancer may effectively
be iatrogenic. If this is the case, it seems dubious to
count the relief of this anxiety as a benefit of a screening
program. In addition, screening itself produces some
psychological harms. False positives in particular, which
cumulate across a lifetime of participation,38 have been
shown to have lasting detrimental effects on psychological
wellbeing of a similar magnitude to a cancer diagnosis.39
Supporting autonomy in screening
Screening can, in itself, promote or support autonomy
by providing information.2 On the surface, this seems
relatively straightforward. A person enters screening
knowing little about their cancer risk, and exits knowing
a great deal more. There are certainly situations in which
this will allow people to make better decisions about their
health care, consistent with their own values.
However, communication within screening programs also
has the potential to undermine autonomy.40 Screening
communication and social marketing sometimes seems
designed to secure high participation rates - even to
coerce participation - rather than support autonomy.33,41
Information is often incomplete because harms are rarely
described and relative instead of absolute risks are often
used.26,33,36,42-44 Relative risks are known to discount harms
and inflate benefits in people’s perceptions, and such
systematic biasing of people’s perceptions has been
criticised as a form of unethical manipulation.45 System
incentives for high screening rates including performance
payments and key performance indicators may encourage
this bias. 25,33,46 Concern has also been expressed that
screening communications that emphasise a responsibility
to screen may make people who decide to refuse
screening feel guilty.37
A more ethically justifiable screening program might
focus on improving people’s understanding of why they
might choose to screen, preserving voluntariness, rather
than pushing people towards participation.19,25,47 Empirical
work shows that people choose differently when they are
better informed;48 informed choosing may also improve
psychological wellbeing by increasing people’s sense
of mastery and self-authorisation.49 The benefit-harm
trade-offs of screening are complex. Supporting people

to understand them is no small task and understanding
should not be assumed.43,50 Sustaining valid consent to
screen may require re-contacting people at intervals,
offering opportunities to reconsider prior decisions and
be informed about changes to screening practices and
evidence.50 While some have argued against providing
citizens with quantitative information about screening
on the grounds that they cannot understand it,51 this is
difficult to justify, and is inconsistent with what informed
citizens consider reasonable.52 Particular care needs to
be taken however, when working with people who are
educationally or socioeconomically disadvantaged,49 and
work is ongoing regarding the provision of appropriate
decision assistance to people with limited literacy and
numeracy.53,54
Other relevant ethical considerations
Screening programs carry large opportunity costs because
they are expensive to run well, so it is important to
periodically assess whether they are providing adequate
health benefit and/or improvements in health equity to
justify that cost.23,26,29,55 Concern has been expressed
that screening may divert funding away from forms of
primary prevention that would have a larger effect on allcause mortality and morbidity,56 or away from providing
necessary care to those who are acutely ill.57-59
Financial strain is a particular problem in user-pays health
systems, where cancer can readily cause bankruptcy. In
some user-pays health systems, people may receive a
positive screening result from a free screening service,
and then not be able to access affordable treatment.60,61
Conversely, unregulated private fee-for-service screening
can generate large cost burdens for public or insurancefunded follow-up services.29 Knowing that one is at high
risk of developing cancer may, in some contexts, make
one less employable or insurable.62 This is just one reason
why confidentiality and privacy are important ethical
issues for screening programs.47
Screening tends to have differential uptake among
people of higher and lower socioeconomic status
and people from different cultural backgrounds.49 An
ethical judgement about this depends on whether or
not it is considered to be in people’s best interests
to participate in a particular kind of screening. It also
depends on how justice is conceived. For example,
if screening programs aim to provide the greatest
possible health improvement for the least well off, they
will be designed very differently than if they are intended
to achieve the largest and most efficient improvement in
aggregated population health.49
As with any health service, there are important issues
to consider regarding how best to involve, and be
accountable to, communities,34 and how to ensure that
screening is provided in a way that is respectful and
culturally appropriate.63
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Does cancer screening serve individual or
common interests?
Decisions about whether screening serves the interests
of a population are distinct from decisions about whether
screening serves the interests of a particular individual.5,25,64
It is not yet clear how to balance these distinct population
and individual-level dimensions of screening activities. 2,41,65
There are advantages to a public approach to screening,
particularly in ensuring standardisation and quality
in service provision. However, from a more individual
perspective, to coerce or manipulate citizens to subject
themselves to invasive procedures for the sake of
achieving a participation target, or changing a populationlevel mortality statistic, seems questionable. Different
individuals have different goals and values, and so will - if
they understand an offer of screening - make different
choices. Even expert policymakers disagree on what
the goals of screening should be, and so what values
should be prioritised in decision making.66 Anya Plutynski
summed up the tension this way:
“Although a narrow utilitarian or expected utility perspective
might simply attach values to lives saved, and so use
any strategy (including representing risk deceptively, or
discounting or hiding cost to patients due to unnecessary
biopsies or overdiagnosis), there are broader issues
at stake. Questions of risk and benefit need to be
supplemented by some discussion of the reasonable
variability in values patients attach to different risks, the
norms of clinician-patient relationships, and what respect
for autonomy and informed consent requires. Questions
about risk and benefit can be better answered once
we know how sensitive or specific are our screening
tools, how prevalent the disease, and thus what the
risks are of false positives. However, we also need to
assess the values behind general versus individually
tailored recommendations, and arguments for and against
individual consultation with clinicians, versus general
recommendations that may benefit some, but not most
patients.”25
The literature regarding the ethics of cancer screening
is relatively new, and still in development. This review
suggests that there are at least two central questions that
need resolution if the field is to advance. The first is to
determine how the competing potential goals of screening
should be prioritised and balanced against one another.
The second related question is the extent to which cancer
screening is an individual clinical service, to which the
principles of clinical ethics apply, and/or a public health
service, to which the principles of public health ethics
apply. These questions provide important challenges to
future research on the ethics of cancer screening.
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